share_log

The InterGroup (NASDAQ:INTG) Stock Crosses Below 200 Day Moving Average of $48.12

Defense World ·  Mar 8, 2023 04:13

The InterGroup Co. (NASDAQ:INTG – Get Rating)'s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $48.12 and traded as low as $42.01. The InterGroup shares last traded at $42.01, with a volume of 105 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, TheStreet downgraded The InterGroup from a "c-" rating to a "d+" rating in a research report on Thursday, January 26th.

Get The InterGroup alerts:

The InterGroup Price Performance

The company has a 50-day simple moving average of $44.70 and a 200 day simple moving average of $48.12.

Institutional Investors Weigh In On The InterGroup

An institutional investor recently bought a new position in The InterGroup stock. Jane Street Group LLC bought a new position in The InterGroup Co. (NASDAQ:INTG – Get Rating) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 3,920 shares of the financial services provider's stock, valued at approximately $201,000. Jane Street Group LLC owned 0.18% of The InterGroup at the end of the most recent quarter. Institutional investors and hedge funds own 1.32% of the company's stock.

The InterGroup Company Profile

(Get Rating)

InterGroup Corp. engages in the purchasing, development, operation, rehabilitation, and disposal of real property of various types and description. It operates through the following business segments: Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations handles the business activities of hotels.

Featured Articles

  • Get a free copy of the StockNews.com research report on The InterGroup (INTG)
  • Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
  • Market Gets "Powelled": S&P 500 Confirms Resistance
  • Rivian Plummets, But Is This 2023's Greatest Buying Opportunity?
  • Ulta Insiders Hold Tight: Sell-Siders Buy
  • Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

Receive News & Ratings for The InterGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The InterGroup and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment